[LCID Study Number: 2017-080WIRB]

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Obeticholic Acid In Subjects With Compensated Cirrhosis Due To Nonalcoholic Steatohepatitis

The primary objectives are to evaluate the effects of OCA treatment compared with placebo on: 1. Histological improvement in fibrosis by assessing the percentage of subjects with improvement in fibrosis by at least 1 stage using the NASH CRN scoring system from Baseline to Month 12 and 2. Safety and tolerability

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3367